Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Hourmant

Showing results (61-70 of 99) with videos related to

Pageof 10
Sort By:
Transplantation Proceedings|April 1, 1990
Human segmental pancreas transplantation with special reference to vascular thrombosisJ Paineau, D Cantarovich, J P Couderc, et al.
Transplantation|March 1, 1989
Anti-interleukin 2 receptor monoclonal antibody in the treatment of ongoing acute rejection episodes of human kidney graft--a pilot studyD Cantarovich, B Le Mauff, M Hourmant, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 1, 1988
Prophylactic use of a monoclonal antibody (33B3.1) directed against interleukin 2 receptor following human renal transplantationD Cantarovich, B Le Mauff, M Hourmant, et al.
Transplantation Proceedings|February 1, 1989
Treatment of acute kidney rejection episodes with monoclonal antibody directed against IL2 receptor: a pilot studyD Cantarovich, B Le Mauff, M Hourmant, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 29, 2000
Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantationD Cantarovich, M Giral-Classe, M Hourmant, et al.
The New England Journal of Medicine|April 26, 1990
Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allograftsJ P Soulillou, D Cantarovich, B Le Mauff, et al.
Transplantation Proceedings|February 1, 1995
Multicenter comparative study of an anti-LFA-1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantationM Hourmant, J Bedrossian, D Durand, et al.
Nephron|January 1, 1983
Plasma exchange in early kidney graft rejection associated with anti-donor antibodiesJ P Soulillou, C Guyot, J Guimbretiere, et al.
Kidney International|September 12, 1998
Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneysM Giral-Classe, M Hourmant, D Cantarovich, et al.
Transplantation Proceedings|February 1, 1995
Anti-LFA-1 adhesion molecule monoclonal antibody in prophylaxis of human kidney allograft rejectionB Le Mauff, M Hourmant, Y Le Meur, et al.
Pageof 10

Showing results (61-70 of 99) with videos related to

Sort By:
Pageof 10
Transplantation Proceedings|April 1, 1990
Human segmental pancreas transplantation with special reference to vascular thrombosisJ Paineau, D Cantarovich, J P Couderc, et al.
Transplantation|March 1, 1989
Anti-interleukin 2 receptor monoclonal antibody in the treatment of ongoing acute rejection episodes of human kidney graft--a pilot studyD Cantarovich, B Le Mauff, M Hourmant, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|February 1, 1988
Prophylactic use of a monoclonal antibody (33B3.1) directed against interleukin 2 receptor following human renal transplantationD Cantarovich, B Le Mauff, M Hourmant, et al.
Transplantation Proceedings|February 1, 1989
Treatment of acute kidney rejection episodes with monoclonal antibody directed against IL2 receptor: a pilot studyD Cantarovich, B Le Mauff, M Hourmant, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|September 29, 2000
Prevention of acute rejection with antithymocyte globulin, avoiding corticosteroids, and delaying cyclosporin after renal transplantationD Cantarovich, M Giral-Classe, M Hourmant, et al.
The New England Journal of Medicine|April 26, 1990
Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allograftsJ P Soulillou, D Cantarovich, B Le Mauff, et al.
Transplantation Proceedings|February 1, 1995
Multicenter comparative study of an anti-LFA-1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantationM Hourmant, J Bedrossian, D Durand, et al.
Nephron|January 1, 1983
Plasma exchange in early kidney graft rejection associated with anti-donor antibodiesJ P Soulillou, C Guyot, J Guimbretiere, et al.
Kidney International|September 12, 1998
Delayed graft function of more than six days strongly decreases long-term survival of transplanted kidneysM Giral-Classe, M Hourmant, D Cantarovich, et al.
Transplantation Proceedings|February 1, 1995
Anti-LFA-1 adhesion molecule monoclonal antibody in prophylaxis of human kidney allograft rejectionB Le Mauff, M Hourmant, Y Le Meur, et al.
Pageof 10